This is taken from Dr Moro's May 7 msg:

"The lab is now fully dedicated to generating revenue in the shortest term possible and we shall update our shareholders soon on our advances toward this goal."

What was the most recent press release regarding China? I haven't followed bocx as closely as some of you, but I was under the impression that test revenue could already be flowing in china, which made me think that product development had matured before the stock market really tanked.

However, if entering China at this time was not -- coincidentally -- part of the original plan, I assume this is simply desperation for product revenue in the face of dried up investment revenue (understandable for any small R&D company right now)

If it is revenue desperation, I'm curious whether a hasty market entrance could somehow backfire (due to poor marketing/preparation/communication) despite the product having great potential. On the other hand, testing in a "closed market" like China's may be shrewd in that it might allow for some market testing without a lot of free world scrutiny while they iron out the bugs.

Has there been any company discussion of this?